MLAB MESA LABORATORIES INC /CO/ Insider Trading

Director Mark Christopher Capone bought 1,301 shares of MLAB at $76.35 on 2026-03-10; cluster pattern with 2 other insiders in 14 days.

Mark Christopher Capone, a director, purchased 1,301 shares at $76.35, raising his position by 61.1% from 2,128 to 3,429 shares. This transaction occurs within a cluster buy pattern—2 other insiders have also bought within the past 14 days—suggesting multiple internal actors are acquiring stock at current levels despite material headwinds. The company faces significant valuation and profitability challenges: it carries a P/E of 107.69, was unprofitable over its most recent full fiscal year, and the stock has declined 47.0% from its 52-week high and 21.5% over the past 30 days. The convergent insider buying activity during a period of sharp price weakness and structural unprofitability warrants investor attention, as it may reflect information or conviction not visible in public market pricing, or conversely, may occur independent of near-term catalysts.

Director Ladiwala purchases 3,500 shares at $72.23 for $252.8K; cluster of 3 insider buys in 14 days amid -21.5% monthly decline.

Director Ladiwala Shabanali purchased 3,500 shares for $252,805.00 at $72.23, increasing his holdings by 69.7% from 5,023 to 8,523 shares. This transaction is part of a cluster buy pattern with 2 other insiders purchasing within the past 14 days, suggesting coordinated or parallel conviction among the company's leadership. The purchase occurred as MESA Labs stock declined 21.5% over the prior 30 days and currently trades 47.0% below its 52-week high, though the company reported 11.5% annual revenue growth and $65.1M in latest quarterly revenue. However, the elevated P/E of 107.69 and the company's negative full-year net income warrant consideration of the valuation context in which this accumulation occurred.

Director Tripeny R Tony bought 1,315 shares of MLAB at $76.00 on 2026-03-10; holdings up 32.2%. Stock now -47.0% from 52-week high. Cluster: 2 other insiders also bought within 14 days.

Director Tripeny R Tony purchased 1,315 shares at $76.00, increasing his stake by 32.2% in a single transaction. The purchase follows a meaningful drawdown: the stock trades at $73.23, down 47.0% from its 52-week high of $138.21 and down 21.5% over the past 30 days. Notably, this buy is part of a cluster pattern—2 other insiders also acquired shares within the past 14 days—suggesting coordinated board or management confidence. However, the company's fundamentals present a mixed picture: while revenue grew 11.5% year-over-year to $65.1M in the latest quarter, the company was unprofitable over its most recent full fiscal year and trades at an elevated P/E of 107.69. The insider's cross-ticker track record shows strong historical returns (avg 90d return +1394.3%, 100% win rate across 1 prior buy), though this metric reflects success across multiple stocks, not necessarily predictive power at MLAB specifically.

Owens, then-CEO of MLAB, sold 21,000 shares ($2.6M) on 2025-03-19 via pre-arranged 10b5-1 plan.

Gary M Owens, who held the title of President and CEO at the time of this transaction, sold 21,000 shares at $123.91 on 2025-03-19 as part of a pre-arranged 10b5-1 trading plan adopted on 2024-09-12. This scheduled sale reduced his holdings from 64,337 shares to 43,337 shares, a -32.6% reduction in his position. Since the trade was governed by a pre-arranged plan rather than executed at the executive's discretion, it reflects a contractual obligation established months earlier and carries no timing signal regarding near-term business outlook. The substantial reduction in holding size—from 64.3K to 43.3K shares—warrants scrutiny into whether the 10b5-1 plan parameters or adoption timing reflected any material considerations at the time of plan establishment in September 2024.

MLAB CEO Gary M Owens sells 5,069 shares for $571,735.87 at blended avg $112.79

Gary M Owens, President and CEO, sold 5,069 shares of MESA LABORATORIES across two separate transactions on 2024-10-28 and 2024-10-29 for a blended average price of $112.79. The sale reduced his holdings by 10.5%, from 48.4K to 43.3K shares, totaling $571,735.87. This occurs in a context where the company has negative full-year net income, annual revenue is flat to declining (-1.3%), and the stock is down 20.0% from its 52-week high of $140.86. The sale occurs at prices ($113.62 and $111.98) near the current market price of $112.68, providing no clear signal about insider timing confidence given the stock's broader 52-week range and recent weakness.